Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma
The Journal of Pharmacology and Experimental Therapeutics, ISSN: 0022-3565, Vol: 354, Issue: 3, Page: 261-268
2015
- 26Citations
- 29Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations26
- Citation Indexes26
- 26
- CrossRef23
- Captures29
- Readers29
- 22
Article Description
The bioactive lipid sphingosine-1-phosphate (S1P) and its receptors (S1P 1–5 ) play critical roles in many pathologic processes, including cancer. The S1P axis has become a bona fide therapeutic target in cancer. JTE-013 [ N -(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1 H -pyrazolo[3,4- b ]pyridin-6-yl]-hydrazinecarboxamide], a known S1P 2 antagonist, suffers from instability in vivo. Structurally modified, more potent, and stable S1P 2 inhibitors would be desirable pharmacological tools. One of the JTE-013 derivatives, AB1 [ N -(1 H -4-isopropyl-1-allyl-3-methylpyrazolo[3,4- b ]pyridine-6-yl)-amino- N ′-(2,6-dichloropyridine-4-yl) urea], exhibited improved S1P 2 antagonism compared with JTE-013. Intravenous pharmacokinetics indicated enhanced stability or slower clearance of AB1 in vivo. Migration assays in glioblastoma showed that AB1 was slightly more effective than JTE-013 in blocking S1P 2 -mediated inhibition of cell migration. Functional studies in the neuroblastoma (NB) cell line SK-N-AS showed that AB1 displayed potency at least equivalent to JTE-013 in affecting signaling molecules downstream of S1P 2. Similarly, AB1 inhibition of the growth of SK-N-AS tumor xenografts was improved compared with JTE-013. Cell viability assays excluded that this enhanced AB1 effect is caused by inhibition of cancer cell survival. Both JTE-013 and AB1 trended to inhibit (C-C motif) ligand 2 expression and were able to significantly inhibit subsequent tumor-associated macrophage infiltration in NB xenografts. Interestingly, AB1 was more effective than JTE-013 in inhibiting the expression of the profibrotic mediator connective tissue growth factor. The terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling assay and cleaved caspase-3 detection further demonstrated that apoptosis was increased in AB1-treated NB xenografts compared with JTE-013. Overall, the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022356524191008; http://dx.doi.org/10.1124/jpet.115.224519; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84941569186&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/26105954; https://linkinghub.elsevier.com/retrieve/pii/S0022356524191008; https://dx.doi.org/10.1124/jpet.115.224519; https://jpet.aspetjournals.org/content/354/3/261
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know